Chronic kidney disease (CKD) affects an estimated 19 million adults in the US, and is associated with an elevated risk of cardiovascular disease (CVD) and mortality. Clinical practice guidelines define CKD on the basis of both albuminuria and decreased kidney function, most frequently assessed by estimating the glomerular filtration rate (eGFR) using serum creatinine (SCr). National organizations have proposed including CKD in CVD risk stratification algorithms, but no large prospective studies to date have combined data on albuminuria and estimated GFR to examine CVD incidence. Recent studies in the elderly suggest Cystatin C (CysC) can provide estimates of kidney function that are more predictive of subsequent GVD events than estimates based on SCr, which are susceptible to biases due to muscle loss. CKD shares several risk factors and pathogenic mechanisms with CVD though the prospective studies of CKD have been limited. The Atherosclerosis Risk in Communities (ARIC) Study has followed 15,792 African Americans and Whites since 1987, and provided important data on CKD risk factors and consequences. We propose to collect new data and conduct systematic analyses to achieve the following aims: 1) Investigate a state of the art assessment of prevalent CKD as an independent risk factor for cardiovascular disease and mortality among 11,336 adults examined in 1996-1998. Prevalent CKD is defined by a combination of decreased kidney function (existing SCr and proposed CysC measures) and kidney damage (albuminuria). 2) Test novel predictors of declining kidney function over 6 years in a nested case-cohort design including -800 cases with estimated GFR<60 ml/min/1.73m2 based on CysC. We will focusing on markers of inflammation and advanced glycation end-products (AGEs), and 3) Identify chromosomal regions and genetic variants predictive of incident CKD. By extending ongoing genotyping we will conduct: (A) genome wide Mapping by Admixture Linkage Disequilibrium (MALD) scan in African-Americans and (B) Candidate gene study of -2,000 genes. Positive results will be tested for replication in additional identified cohorts (Jackson Heart Study, Framingham Heart Study and the Cardiovascular Heart Study). This proposal directly addresses several questions relevant to current policy issues, including how best to quantify CKD and incorporate it into CVD risk prediction algorithms. In addition, it will provide much-needed data to be shared with the larger scientific community on serologic and genetic risk factors for CKD, a growing public health concern in the US.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK076770-05
Application #
8018537
Study Section
Kidney, Nutrition, Obesity and Diabetes (KNOD)
Program Officer
Eggers, Paul Wayne
Project Start
2007-02-01
Project End
2014-01-31
Budget Start
2011-02-01
Budget End
2014-01-31
Support Year
5
Fiscal Year
2011
Total Cost
$622,648
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Folsom, A R; Lutsey, P L; Heckbert, S R et al. (2018) Longitudinal increases in blood biomarkers of inflammation or cardiovascular disease and the incidence of venous thromboembolism. J Thromb Haemost 16:1964-1972
Maruthur, Nisa M; Li, Man; Halushka, Marc K et al. (2015) Genetics of Plasma Soluble Receptor for Advanced Glycation End-Products and Cardiovascular Outcomes in a Community-based Population: Results from the Atherosclerosis Risk in Communities Study. PLoS One 10:e0128452
Rebholz, Casey M; Astor, Brad C; Grams, Morgan E et al. (2015) Association of plasma levels of soluble receptor for advanced glycation end products and risk of kidney disease: the Atherosclerosis Risk in Communities study. Nephrol Dial Transplant 30:77-83
Al Rifai, Mahmoud; Schneider, Andrea L C; Alonso, Alvaro et al. (2015) sRAGE, inflammation, and risk of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Diabetes Complications 29:180-5
Lazo, Mariana; Halushka, Marc K; Shen, Lu et al. (2015) Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study. Am Heart J 170:961-7
Rebholz, Casey M; Grams, Morgan E; Matsushita, Kunihiro et al. (2015) Change in Multiple Filtration Markers and Subsequent Risk of Cardiovascular Disease and Mortality. Clin J Am Soc Nephrol 10:941-8
Rebholz, Casey M; Grams, Morgan E; Matsushita, Kunihiro et al. (2015) Change in novel filtration markers and risk of ESRD. Am J Kidney Dis 66:47-54
Greenberg, Keiko I; McAdams-DeMarco, Mara A; Köttgen, Anna et al. (2015) Plasma Urate and Risk of a Hospital Stay with AKI: The Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol 10:776-83
Naik, Rakhi P; Derebail, Vimal K; Grams, Morgan E et al. (2014) Association of sickle cell trait with chronic kidney disease and albuminuria in African Americans. JAMA 312:2115-25
Bower, Julie K; Pankow, James S; Lazo, Mariana et al. (2014) Three-year variability in plasma concentrations of the soluble receptor for advanced glycation end products (sRAGE). Clin Biochem 47:132-4

Showing the most recent 10 out of 52 publications